Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.

ABSTRACT:

Aim

To investigate the long-term clinical benefit of dual antiplatelet therapy with potent P2Y12 inhibitors compared to clopidogrel in patients with acute coronary syndrome (ACS).

Methods

In this prospective multicenter observational study, we enrolled 708 patients with ACS treated with clopidogrel (n = 137), ticagrelor (n = 260) or prasugrel (n = 311). Major adverse cardiac events (MACE; over 1 year) and long-term mortality (median: 5.6 years; interquartile range [IQR] 4.9-6.5 years) were assessed. Multiple electrode aggregometry (MEA) was used to measure adenosine diphosphate (ADP)- and arachidonic acid (AA)-induced platelet aggregation.

Results

Type of P2Y12 inhibitor emerged as an independent predictor of long-term mortality and MACE: patients treated with potent

SUBMITTER: Gager GM 

PROVIDER: S-EPMC7685125 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature